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Abstract
Background: To compare the magnetic resonance imaging (MRI) features of ovarian clear cell carcinoma (CCC) and
high-grade serous carcinoma (HGSC), to distinguish CCC from HGSC.
Methods: MRI features (laterality, shape, size, configuration, papillary projection, signal intensity, enhancement,
peritoneal implant, lymphadenopathy, ascites) of 40 tumors in 37 patients with CCC, confirmed by surgery and
pathology, were compared with those of 62 tumors in 40 patients with HGSC. Statistical analysis was performed
using Mann-Whitney and Fisher’s exact tests.
Results: There was a statistically significant difference in the mean maximum diameter, laterality, and FIGO stage
(P = 0.002, P < 0.001, P < 0.001, respectively) between CCC and HGSC. Compared to HGSCs, CCCs were more
frequently oval (30/40, 75 % vs 12/62, 19 %; P < 0.001), more often cystic (21/40, 53 % vs 8/62, 13 %; P < 0.001)
and unilocular (23/29, 79 % vs 7/31, 23 %; P < 0.001), had T1-hyperintense cystic components more often (18/29,
62 % vs 5/29, 17 %; P < 0.001), had larger papillary projections (5.13 ± 0.4 cm vs 2.91 ± 0.3 cm; P < 0.001), were peritoneally
implanted less frequently (P = 0.001) and had fewer ascites (P < 0.001).
Conclusions: CCC typically showed an oval, unilocular cystic mass with large papillary projection and T1-hyperintense
cystic components. MRI could be helpful for distinguishing CCC from HGSC.
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Background
Clear cell carcinoma (CCC) has recently emerged as the
second most common type of epithelial ovarian cancers
(EOCs), representing 5–25 % of ovarian carcinomas. CCC
is a highly distinct entity from ovarian high-grade serous
carcinoma (HGSC), which is the most frequent subtype of
EOCs [1, 2]. Compared with ovarian HGSCs, CCCs
present at a younger age, have a higher incidence of stage
I disease, rarely occur bilaterally, and often consist of large
pelvic mass in association with endometriosis [3–5]. It has
been widely assumed that most CCCs appear resistant to
conventional chemotherapeutic agents and have relatively
poorer prognoses than other EOC subtypes when they
are in advanced stages [4–6]. However, patients with
early stage CCC might have better prognoses than pa-
tients with HGSC and might not require any adjuvant
therapy [4, 7, 8]. Given their distinctive biological and
clinical features, the therapeutic strategy for ovarian
CCC is different from that for HGSC in the 2014 ver-
sion of the National Comprehensive Cancer Network
(NCCN) guidelines [9]. Therefore, early detection and
accurate preoperative diagnosis of ovarian CCC are of
critical importance for an optimal therapeutic strategy
in this epoch of precision medicine.
Owing to multiplanar imaging and its superior capabil-
ity for soft tissue contrast, magnetic resonance imaging
(MRI) has the ability to characterize complex adnexal
masses and could contribute to the correct identification
of CCC [10, 11]. To date, only a few case reports and a
* Correspondence: dr.jinweiqiang@163.com; guofuzh@fudan.edu.cn
2Department of Radiology, Jinshan Hospital, Shanghai Medical College,
Fudan University, 1508 Longhang Road, Shanghai 201508, Jinshan District,
China
1Department of Radiology, Obstetrics & Gynecology Hospital, Shanghai
Medical College, Fudan University, 419 Fangxie Road, Shanghai 200011,
Huangpu District, China
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Ma et al. Journal of Ovarian Research  (2016) 9:40 
DOI 10.1186/s13048-016-0251-x
small sample of MRI studies concerning CCC have been
available [12, 13]. Furthermore, differentiation between
CCC and HGSC has not yet been investigated. Therefore,
the purposes of this study were to investigate the charac-
teristic features of CCC and to evaluate MRI for distin-
guishing CCC from HGSC.
Methods
Clinical data
This retrospective study was approved by the two institu-
tional review boards of Jinshan Hospital and Obstetrics &
Gynecology Hospital, Shanghai Medical College, Fudan
University, China. The informed consent requirement was
waived. From February 2008 to December 2014, patients
suspected of ovarian tumors by gynecologic examination,
biomarkers, US or CT were enrolled in a MRI study pro-
ject of ovarian tumor. Among 530 cases proven by surgery
and histology, a total of 37 patients with 40 pure CCCs,
confirmed by surgery and histopathology, were found. We
excluded 6 patients with CCC mixed with other types of
EOC and and patients with recurrent tumors were also
excluded. Pelvic masses were found in 27 (73 %) patients
during routine physical examinations, and the remaining
10 patients presented with non-specific symptoms, such
as abdominal pain (22 %) and loss of weight (5 %).
For comparison, a total of 40 patients with 62 primary
HGSCs were randomly selected from the same databases
during the same period as the control group. All of the
patients in both groups underwent surgery (laparoscopy
in 4 cases, laparotomy in 73 cases) within two weeks after
completing MRI scans. The tumors were staged according
to the International Federation of Gynecology and Obstet-
rics (FIGO) 2013 staging system.
MRI scanning
Images were acquired with 1.5 T MR scanner (Sym-
phony or Avanto, Siemens, Erlangen, Germany), with a
phased-array pelvic coil. The patient lay in the supine
position and breathed freely during image acquisition.
The following sequences were obtained: axial spin-echo
(SE) T1-weighted imaging (T1WI) (repetition time [TR]/
echo time [TE] = 761/10 ms); T1WI flash 2D with fat
saturation [TR/TE = 196/2.9 ms]; turbo SE T2-weighted
imaging [T2WI] with and without fat saturation [TR/
TE = 8000/83 ms and 4000/98 ms, respectively], and
turbo SE sagittal and coronal T2WI (TR/TE = 8000/
98 ms). Contrast-enhanced flash 2D T1WI with fat sat-
uration (TR/TE = 196/2.9 ms) was performed on the
axial and sagittal planes after the intravenous administra-
tion of 0.2 mmol/kg Gadopentetate dimeglumine (Gd-
DTPA, Magnevist; Bayer Schering, Berlin, Germany) at a
rate of 2–3 ml/second. The scanning parameters were as
follows: slice thickness 5 mm; gap 1.5 mm; matrix 256 ×
256; field of view 20–25 cm× 34 cm; and excitations 4.
Table 1 Comparison of clinical features between ovarian CCC
and HGSC
Clinical features CCC (n = 37) HGSC (n = 40) P value
Mean age 51 ± 1.4 54 ± 1.4 0.231
Mean diameter 11.4 ± 0.7 8.6 ± 0.6 0.002
Laterality <0.001
Unilateral 34 (91 %) 18 (45 %)
Bilateral 3 (9 %) 22 (55 %)
Menopausal status 0.459
Postmenopausal 21 (57 %) 26 (65 %)
Premenopausal 16 (43 %) 14 (35 %)
Surgical approach 0.268
Laparotomy 34 (92 %) 39 (98 %)
Laparoscopy 3 (8 %) 1 (2 %)
FIGO stage <0.001
I 23 (62 %) 4 (10 %)
II 5 (14 %) 6 (15 %)
III 8 (23 %) 27 (68 %)
IV 1 (3 %) 3 (7 %)
CCC clear cell carcinoma, HGSC high-grade serous carcinoma, FIGO International
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P value Odds Ratio
Shape <0.001 12.5 (4.8 ~ 32.4)
Oval 30 (75 %) 12 (19 %)
Irregular 10 (25 %) 50 (81 %)
Configuration <0.001 0.2 (0.1 ~ 0.4)
Cystic 21 (53 %) 8 (13 %)
Cystic-solid 8 (20 %) 21 (34 %)
Solid 11(27 %) 33 (53 %)
Unilocular 23/29 (79 %) 7/31 (23 %) <0.001 19.9 (5.4 ~ 74.1)
Papillary projections 26 (70 %) 31 (50 %) 0.073 ——
Size of papillary
projectiona
5.13 ± 0.4 2.91 ± 0.3 <0.001 9.5(1.2 ~ 88.4)
T1-hyperintense
cystic component
18/29 (62 %) 5/29 (17 %) <0.001 8.5 (2.5 ~ 28.7)
Enhancement 0.717 ——
Mild 2 (5 %) 2 (3 %)
Moderate 7 (17 %) 8 (13 %)
Prominent 31 (78 %) 52 (84 %)
Peritoneal
implantationb
1 (3 %) 12 (30 %) 0.001 0.1 (0.01 ~ 0.7)
Lymphadenopathyb 7 (19 %) 8 (20 %) 0.905 ——
Ascitesb 13 (35 %) 32 (85 %) <0.001 0.2 (0.5 ~ 0.4)
MRI magnetic resonance imaging; amean maximal size of papillary projection;
bNo. (percentage) in 37 patients with CCC and 40 patients with HGSC
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The scanning range was from the inferior public symphy-
sis to the renal hilum and extended beyond the dome of
the tumor in cases with large masses.
Image analysis
The MRIs were reviewed independently by two radiologists
(F.H.M. and J.W.Q.) who had 12 and 31 years of experi-
ence, respectively, in gynecological imaging. Both of the
radiologists were blinded to the pathological results. Any
discrepancies were resolved by consensus. Tumor size,
presence and relative signal intensity of a solid and/or cystic
component, presence and number of septa, degrees of en-
hancement and associated findings (ascites, endometriosis,
peritoneal implants, lymphadenopathy and distant metasta-
sis) were recorded on both T2WI and contrast-enhanced
T1WI. The cystic and solid component was defined as
tissue with on enhancement and enhancement after in-
jection respectively. The relative signal intensity and
degrees of enhancement of a solid and/or cystic compo-
nent were referring to the signal intensity and enhance-
ment of outer myometrium. Tumors were classified as
predominantly cystic, mixed cystic-solid, or solid. The
size of tumor, septa and solid component were mea-
sured on the contrast-enhanced T1WI.
Histopathology
The histopathological evaluation was performed by two
pathologists who specialized in gynecological path-
ology, and the diagnosis was determined by consensus.
Data were recorded on a standardized form specific-
ally designed for ovarian tumors and included lateral-
ity, tumor size, shape and color, and cystic and solid
components.
Statistical analysis
Statistical analysis was performed with SPSS software, ver-
sion 17.0 for Windows (SPSS Inc., Chicago, IL, USA). The
differences between CCC and HGSC in laterality, shape,
configuration, unilocularity, papillary projections, signal
intensity on T1WI, enhancement and associated findings
were compared using Pearson’s Chi-square test or Fisher’s
exact test, and age and size were compared using the
Mann-Whitney test. Binary logistic regression was used
to assess the predictive value of MRI findings for CCC.
A p-value less than 0.05 was considered to be statisti-
cally significant. The diagnostic performance of the sig-
nificant MRI features for characterizing ovarian CCC
was also determined.
Fig. 1 A 53-year-old woman with left ovarian clear cell carcinoma (CCC). Axial and sagittal turbo spin echo (TSE) T2-weighted imaging (T2WI) with
fat saturation (FS) (a-b) show an oval unilocular cystic mass with papillary projections (arrows). Axial and sagittal contrast-enhanced flash 2D T1WI
with FS (c-d) show prominent enhancements in solid components
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Fig. 2 A 50-year-old woman with bilateral high-grade serous carcinoma (HGSC). Axial and sagittal TSE T2WI with FS (a-b), axial T1WI (c) and sagittal
contrast-enhanced flash 2D T1WI with FS (d) show the irregular solid mass appearing with iso-intensity on T1WI and prominent enhancement on
contrast-enhanced T1WI. There are peritoneal implantations (white stars) in the vesico- and rectouterine pouches and lymphadenopathy (arrows) in
front of the left iliac vessels (FIGO stage IIIc)
Fig. 3 An 81-year-old woman with CCC in the left ovary. Axial SE T1WI, axial and sagittal TSE T2WI with FS (a, b, c) demonstrate a unilocular cystic
mass with a large papillary projection, with prominent enhancement on contrast-enhanced flash 2D T1WI with FS (d, e). Pathologic specimen (f)
of the mass shows a large papillary projection protruding into the lumen
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Results
Ten of 40 CCCs were found to arise from endometri-
osis, and 4 evolved from borderline clear cell tumors.
The clinical features of CCC compared with HGSC are
shown in Table 1. There was a statistically significant
difference in the maximum diameter, laterality, and
FIGO stage (P = 0.002, P <0.001, P <0.001, respectively)
between CCC and HGSC. No statistically significant dif-
ferences were found in age, menopause status, or surgical
approach (P = 0.231, 0.459, 0.268, respectively) between
the two groups.
The MRI features of CCC compared with HGSC are
shown in Table 2. Compared to HGSC, CCC appeared to
be more frequently oval (30/40, 75 % vs 12/62, 19 %) and
less frequently irregular (10/40, 25 % vs 50/62, 81 %),
more often cystic (21/40, 53 % vs 8/62, 13 %), less often
mixed cystic-solid (8/40, 20 % vs 21/62, 34 % and solid
(11/40, 27 % vs 33/62, 53 %), and more often unilocular
(23/29, 79 % vs 7/31, 23 %), with significant differences
(all P < 0.001) (Figs. 1 and 2). Papillary projections were
found in 65 % (26/40) of CCCs versus 50 % (31/62) of
HGSCs (P = 0.073) and were larger in CCCs (5.13 ±
0.4 cm) than in HGSCs (2.91 ± 0.3 cm) (P <0.001) (Figs. 3
and 4). The signal of the cystic component on T1WI was
hyperintense in 62 % (18/29) of CCCs versus iso- or
hypointense in 83 % (24/29) of HGSCs (P <0.001) (Fig. 5).
The enhancement was mild in 5 %, moderate in 17 % and
prominent in 78 % of CCCs versus 3 %, 13 %, 84 % of
HGSCs, respectively (P = 0.717). There was statistically
significant difference between the two groups in peri-
toneal implantation (P = 0.001) and ascites (P <0.001).
Using binary logistic regression analysis, the most signifi-
cant predictive features of CCC were a unilocular cystic
mass (Odds ratio[OR] = 19.9, 95 % confidence interval [CI]:
5.4–74.1), oval shape (OR = 12.5, 95 %; 4.8–32.4), large pap-
illary projections (OR = 9.5, 95 % CI: 1.2–88.4), and hyper-
intensity on T1WI (OR= 8.5, 95 % CI: 2.5–28.7).
Diagnostic performances for the characterization of
CCC are listed in Table 3. The combination of any two
of four features – a unilocular cystic mass, oval shape,
large papillary projections (≥4 cm) and hyperintensity
on T1WI – yielded sensitivity, specificity, accuracy,
positive and negative predictive values, and a positive
likelihood ratio for identifying CCC of 90 % (36/40), 87 %
(54/62), 88 % (90/102), 82 % (36/44), 93 % (54/58), and
6.92, respectively.
Discussion
Ovarian carcinomas comprise a heterogeneous group of
tumors, the four most common subtypes being serous,
Fig. 4 A 42-year-old woman with HGSC in the right ovary. Axial SE T1WI and TSE T2WI with FS (a-b) show a mulitlocular cystic mass with multiple
small papillary projections. Axial and sagittal contrast-enhanced flash 2D T1WI with FS (c-d) show the prominently enhanced papillary projections
(arrowheads) and lymphadenopathy (arrows) beside the bilateral iliac vessels
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endometrioid, clear cell and mucinous. In recent years,
considerable advances have been achieved in the under-
standing and identification of the underlying pathogenesis
in different subtypes [1, 14]. Our previous study showed
that conventional MRI combining DWI may be helpful
for differentiating ovarian endometrioid carcinomas from
HGSC [15]. Previous studies have indicated that there
are different risk factors, origins, genetic alterations,
biological behaviors, clinicopathological characteristics
and chemotherapy sensitivities between ovarian CCC
and HGSC [2–6, 16]. In our clinical practice, we also
have found the MRI features between CCC and HGSC
may be different. So we try to investigate the character-
istic features of CCC and to evaluate MRI for distin-
guishing CCC from HGSC.
Clinically, patients with CCC are more likely to
present with a unilateral (89–95 %), large pelvic mass
(12 cm–13.5 cm) and stage I disease (56–63 %) in asso-
ciation with endometriosis (31–48 %) [5, 17, 18]. In con-
trast, patients with HGSC are more likely to be present
with a bilateral (50 %), medium-sized mass (8.6 cm) and
advanced stage disease (81 %) [5, 17]. In this study, signifi-
cant differences were found in unilaterality (91 % vs 55 %),
mass size (11.4 cm vs 8.6 cm) and stage I disease (62 % vs
10 %) between ovarian CCCs and HGSCs. Ovarian CCCs
were confirmed to be derived from the endometriosis in
25 % of the patients, which was an incidence lower than
those in previous studies [17, 18]. A possible explanation
for this result was insufficient sampling due to the study
not being pathogenesis-oriented. In contrast, most ovarian
Fig. 5 A 49-year-old woman with CCC in the right ovary. Axial SE T1WI, axial and sagittal TSE T2WI with FS (a-c) demonstrate a unilocular cystic
mass with multiple papillary projections (arrows). The signal intensity of the cystic component is high on both T1WI and T2WI (white stars). The
papillae show prominent enhancement on contrast-enhanced flash 2D T1WI with FS (d)
Table 3 Diagnostic performance of MRI features for characterizing ovarian CCC
MRI features Sensitivity (%) Specificity (%) Accuracy (%) PPV (%) NPV (%) PLR
Unilocular cystic mass 90 (26/29) 89 (24/31) 83 (50/60) 79 (26/33) 89 (24/27) 8.18
Oval shape 75 (30/40) 82 (51/62) 79 (81/102) 73 (30/41) 84 (51/61) 4.16
Papillary projections (≥3 cm) 85 (24/28) 71 (21/31) 76 (46/59) 71 (24/34) 76 (21/25) 2.93
T1-hyperintense cystic component 62 (18/29) 84 (26/31) 73 (44/60) 78 (18/23) 70 (26/37) 3.88
Data in parentheses are the numbers of masses; PPV positive predictive value, NPV negative predictive value, PLR positive likelihood ratio
Ma et al. Journal of Ovarian Research  (2016) 9:40 Page 6 of 8
HGSCs are believed to derive from the tubal intraepithe-
lial lining [19], and only 7 % of cases have histories of
ovarian endometriosis [20].
Although a specific histologic type could not be diag-
nosed on the basis of MR imaging, some imaging features
were more common and more suggestive of one or some
histologic types. For example, unilocular cystic masses
with one or more nodules protruding into the lumen con-
stitute a typical appearance of CCC [12, 13]. This typical
appearance was seen in 65 % (26/40) of our CCCs, while
multilocular mixed cystic-solid masses with small papillary
projections and solid masses were the typical features of
HGSCs.
The identification of papillary projections on MR im-
ages is important because they are the best predictors
of an epithelial tumor and can be correlated with the
aggressiveness of the tumor [21]. Histologically, they
represent folds of epithelial proliferation growing over a
stromal core. Papillary projections in differentiating be-
nign tumors from borderline or malignant counterparts
have been reported [21, 22]. However, to our know-
ledge, no attempts were made to use these projections
to distinguish the different subtypes of EOC. In this study,
there was no significant difference in the presence of
papillary projections between CCC and HGSC. How-
ever, the mean size of the papillary projections was sig-
nificantly larger in CCC than in HGSC (5.13 ± 0.4 cm
vs 2.91 ± 0.3 cm), which was inconsistent with the find-
ings of Buy et al [23]. On microscopy, the papillae of
HGSC are small, irregular, and hierarchically branching,
in contrast with the large, round, and more simplified
papillae of CCC [1, 24].
The signal of the cystic components on T1WI was
hyperintense in 62 % of CCCs versus iso- or hypoin-
tense in 83 % of HGSCs, similar to pelvic muscle or
equal to urine. The high intensity of the cystic compo-
nents, indicating high attenuation on CT, as reported
by Choi et al. [13], might be caused by the presence of
intracystic hemorrhage from associated endometriosis.
We believe that this high intensity could be one of the
points for distinguishing CCC from HGSC.
Cystic-solid and solid masses were less common in
CCCs (47 %) than in HGSCs (87 %). The enhancement of
solid components on contrast-enhancement MRI did not
help in distinguishing between CCC and HGSC; however,
the shape of mass could be a differentiating feature, with
more oval and fewer irregular masses in CCCs than in
HGSCs. Associated findings, such as ascites, endometri-
osis, and peritoneal implantation, might also be important
points of distinction between CCC and HGSC. Massive
ascites and peritoneal implants were strongly indicative of
HGSC, while endometriosis was indicative of CCC.
There were some limitations of our study. First, only a
limited number of patients were evaluated, and selection
bias was inevitably present due to the retrospective nature
of the study. Second, the value of functional imaging, such
as diffusion- and perfusion-weighted imaging and spec-
troscopy, was not investigated. Third, inter-reader vari-
ability was not assessed.
Conclusion
Our preliminary study showed that a large unilocular,
cystic mass and papillary projections were the typical
features of CCC. The size, laterality, FIGO stage, shape,
configuration, unilocularity, T1-hyperintense cystic com-
ponent, papillary projection size, peritoneal implant and
ascites were the ten features that were helpful for distin-
guishing CCC from HGSC.
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